Everest Medicines Announces Approval of ‘B’ Marker Removal from Company’s Stock Code by the Hong Kong Stock Exchange
SHANGHAI, Apr 22, 2025 – (ACN Newswire) – Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) has approved the Company’s application to remove the “B” marker from its
SHANGHAI, Apr 22, 2025 – (ACN Newswire) – Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) has approved the Company’s application to remove the “B” marker from its stock short name…
Read More
About Author
